文献速递类风湿关节炎

用于支持类风湿关节炎患者床旁共享决策的偏好表型:一项概念验证研究

Preference Phenotypes in Support of Shared Decision-Making at Point-of-Care for Patients With Rheumatoid Arthritis: A Proof-of-Concept Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-04-08

这项概念验证研究采用前后测设计,评估一种让患者查看类风湿关节炎治疗偏好表型的价值澄清工具能否在床旁支持共享决策。纳入46次前测和40次后测的预定门诊随访,对活动性类风湿关节炎患者的访视进行转录并用定量编码方案测量共享决策成分。结果显示后测访视中医师提供2种或以上改善病情抗风湿药的比例为60%(前测47.8%),患者更多表达价值观和偏好,医师更可能基于患者价值观和偏好提出推荐,且访视时间未延长。

要点

  • 后测访视中医师提供2种或以上改善病情抗风湿药的比例为60%,前测为47.8%。
  • 后测访视中患者表达价值观和偏好的比例更高,涉及1种新改善病情抗风湿药决策时为90.9%对56.3%。
  • 后测访视中医师基于患者价值观和偏好提出推荐的比例为100%(6次访视中),前测为64.3%(14次访视中)。

核心结论

  • 这项研究提供早期迹象表明,让患者考虑一组偏好表型的价值澄清工具可在不延长访视时间的情况下支持床旁共享决策。

研究设计与样本

  • 采用前后测设计的概念验证研究,纳入预定门诊随访的英语类风湿关节炎患者,对活动性类风湿关节炎患者的访视进行转录,并使用基于既定共享决策模型的定量编码方案测量共享决策成分。
  • 前测阶段纳入46次访视,后测阶段纳入40次访视。

主要发现

  • 后测访视中医师提供2种或以上改善病情抗风湿药的比例为60%,前测访视为47.8%。
  • 后测访视中患者表达价值观和/或偏好的比例高于前测:涉及1种新改善病情抗风湿药选择时为90.9%对56.3%,涉及2种或以上新改善病情抗风湿药时为95.8%对86.4%,涉及泼尼松时为87.5%对66.7%。
  • 在提出推荐的访视中,后测阶段医师基于患者价值观和/或偏好提出推荐的比例为100%(6次访视中),前测阶段为64.3%(14次访视中)。
  • 前测阶段访视平均时长为29.9±11.6分钟,后测阶段为25.1±10.7分钟。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In this proof-of-concept study, we sought to evaluate whether a value clarification tool enabling patients to view a set of rheumatoid arthritis (RA) treatment preference phenotypes could be used to support shared decision-making at the point-of-care. METHODS: We conducted a pretest/post test study. English-speaking patients with RA presenting to their scheduled outpatient visits were asked to participate. Visits for patients with active RA were transcribed. Shared decision-making components were measured using a quantitative coding scheme based on an established model of shared decision-making. RESULTS: Forty-six visits were included in the pretest and 40 in the post test phases. Providers offered more disease-modifying antirheumatic drugs (DMARDs) (2 or more) in the post test visits (60%) compared to the pretest visits (47.8%). Overall, more patients vocalized their values and/or preferences in the post test visits compared to the pretest visits for treatment escalation decisions including a choice of 1 new DMARD (90.9% versus 56.3%), 2 or more new DMARDs (95.8% versus 86.4%), as well as prednisone (87.5% versus 66.7%). Providers were also more likely to base their recommendations on patients' values and/or preferences in the post test (100% of 6 visits) than the pretest (64.3% of 14 visits) phases during visits in which a recommendation was made. The mean ± SD length of the visit was 29.9 ± 11.6 minutes and 25.1 ± 10.7 minutes in the pretest and post test phases, respectively. CONCLUSION: This study provides an early indication that a value clarification tool allowing patients to consider a set of preference phenotypes can support shared decision-making at the point-of-care without extending visit time.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Hsiao B, Binder-Finnema P, Nowell WB, et al. Preference Phenotypes in Support of Shared Decision-Making at Point-of-Care for Patients With Rheumatoid Arthritis: A Proof-of-Concept Study. Arthritis Care Res (Hoboken). 2019. PMID: 29953733. doi:10.1002/acr.23684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。